At What Age Do You Stop Seeing a Gynecologist?

There is no age at which gynecologic care becomes unnecessary. What changes are the specific screenings you need and how often you need them. Most guidelines recommend stopping routine cervical cancer screening around age 65, provided your screening history has been consistently normal, but that single recommendation has been widely misread as permission to stop seeing a gynecologist altogether. In reality, conditions like pelvic floor disorders, vulvar skin diseases, and the genitourinary effects of menopause become more common with age, not less, and a gynecologist is often the specialist best equipped to manage them.

When Cervical Cancer Screening Ends

The guideline most people are thinking of when they ask this question involves Pap smears and HPV testing. The American Cancer Society recommends that people over 65 who have no history of significant cervical precancer in the past 25 years, and who have a documented record of adequate negative screening over the prior 10 years, can stop cervical cancer screening entirely.¹ The U.S. Preventive Services Task Force and the American College of Obstetricians and Gynecologists land in the same range, generally setting 65 as the stop point if your recent history is clean.²

Those two qualifying phrases matter a lot: “no significant precancer” and “adequate negative screening.” If you skipped screenings during your 50s and 60s, you haven’t earned the green light to stop. French guidelines make this point explicitly: the protective effect depends on having at least two normal Pap smears between ages 50 and 65, and patients without that follow-up remain at risk for invasive cancer afterward.³ If your screening record has gaps, your provider may recommend continuing.

The Problem With Treating 65 as a Hard Cutoff

Roughly a fifth of new cervical cancer cases occur in women over 65.⁴ That is a significant share for a cancer that screening is supposed to catch. German registry data paints a starker picture: when researchers corrected for hysterectomy rates, the incidence in women aged 70 to 79 was about 23 new cases per 100,000, and women diagnosed at 65 or older were more often found at a late stage, with a five-year survival rate around 47% compared with roughly 77% in younger patients.⁵

Part of this problem is that women who develop cervical cancer after 65 are disproportionately those who were never screened consistently in the first place. The guideline assumes you followed the screening schedule. If you did not, stopping at 65 carries real risk. A conversation with your gynecologist about your actual screening history is the only way to know whether stopping makes sense for you specifically.

Screening Ages Vary Around the World

The age-65 cutoff is not universal. A systematic review of national guidelines across 11 countries found that while the majority recommend stopping routine cervical cancer screening at 65, Canada extends it to 69 and Australia to 70 to 74.⁶ There is also variation in what test is recommended and how often, with specialty societies in the U.S. tending to suggest more intensive screening than their counterparts in other high-income countries.⁷ If you have lived in or received care in multiple countries, the standards you were screened under may differ, which is worth mentioning to your provider.

Mammography and Breast Health After 74

Breast cancer screening has its own age-related gray zone, and for many people the gynecologist is the one ordering or coordinating mammograms. Screening mammography has proven effective at reducing breast cancer deaths in women between 50 and 74, but most major organizations stop short of recommending it for women over 74 simply because there is limited clinical trial evidence in that group.⁸ European guidelines similarly frame their screening recommendations for women up to age 75.⁹

That “no recommendation” for older women is not the same thing as “stop.” It means the data is thin and the decision becomes individualized. One modeling study found that continuing mammography to age 79 in all women prevented a small number of additional breast cancer deaths but added only about seven hours to average life expectancy, at a high cost per year of life saved. Targeting continued screening to women with higher bone density, a marker for higher breast cancer risk, was substantially more cost-effective.¹⁰ The takeaway is that blanket screening past 74 may not help most women, but it can help some. The conversation should be about your personal risk, not just your age.

Why Life Expectancy Matters More Than Age

Researchers increasingly argue that screening decisions in older adults should be driven by estimated life expectancy rather than calendar age. Cancer screening generally takes more than 10 years to deliver its mortality benefit, so someone whose life expectancy is under 10 years is unlikely to benefit from continued screening and may be exposed to unnecessary procedures, anxiety, and false positives.¹¹ A healthy 68-year-old with a 20-year life expectancy is in a very different position than a frail 68-year-old with a five-year outlook, even though both are the same age on paper. This is the framework many geriatricians and gynecologists now use to decide whether to continue or stop screening.

The Pelvic Exam Debate

Separate from the question of screening tests is the question of the routine pelvic exam itself. And here the medical community disagrees with itself. The American College of Physicians issued a guideline recommending against routine annual pelvic exams in asymptomatic average-risk women, concluding that the evidence of benefit was insufficient. The American College of Obstetricians and Gynecologists disagreed and continued to recommend annual pelvic exams, reaffirming that position even after the ACP guideline was published.¹² The USPSTF, for its part, concluded that the evidence was simply insufficient to assess the balance of benefits and harms.¹³

What this means in practice is that whether you receive an annual pelvic exam after 65 depends heavily on which doctor you see and which guidelines they follow. If you have symptoms, of course, the exam is diagnostic and not controversial. The disagreement is about asymptomatic screening, and it remains unresolved.

Genitourinary Syndrome of Menopause

One of the strongest reasons to maintain a relationship with a gynecologist well past 65 has nothing to do with cancer screening. Genitourinary syndrome of menopause, or GSM, is a broad collection of symptoms caused by the loss of estrogen after menopause. Vaginal dryness, irritation, burning, urinary urgency, painful sex, and recurrent urinary tract infections are all part of the picture. It affects roughly 27% to 84% of postmenopausal women, depending on which symptoms are measured and how studies define the condition.¹⁴ With women now spending about 40% of their lives in the postmenopausal state, this is not a brief transitional phase but a long-term condition.¹⁵

GSM is widely underdiagnosed and undertreated. Many women assume that vaginal dryness and discomfort are just inevitable parts of aging that they should accept. They are not. Over-the-counter lubricants and moisturizers are the most commonly used treatments, followed by low-dose vaginal estrogen, which remains effective and carries a different risk profile than systemic hormone therapy.¹⁶ But many women never bring it up, and many primary care providers never ask. Midlife women are often unaware that there are treatable medical conditions underlying their symptoms, or that safe treatments exist. A gynecologist who manages menopausal health is the most likely provider to catch and address this.

Vulvar Skin Conditions That Peak After Menopause

Lichen sclerosus is a chronic inflammatory skin condition that most commonly affects the vulva, and its incidence peaks in postmenopausal women. Finnish registry data found that the age-specific incidence rate was highest in postmenopausal women, reaching 24 to 53 per 100,000 woman-years, and that vulvar cancer mortality was sharply elevated in women diagnosed with the condition.¹⁷ A retrospective analysis found that when lichen sclerosus did progress to vulvar cancer, the average age at onset of the cancer-associated disease was around 68.¹⁸

Lichen sclerosus causes intense itching, thinning of the skin, and, if untreated, scarring that can distort the vulvar anatomy. It requires long-term monitoring because of the association with vulvar cancer. This is exactly the kind of condition that a gynecologist manages and that a primary care doctor may not examine for. If you stop seeing a gynecologist at 65, a slow-developing vulvar condition can go unnoticed for years.

Postmenopausal Bleeding Is Never Normal

Any vaginal bleeding that occurs after menopause warrants prompt evaluation, regardless of how old you are. A study of older patients presenting with postmenopausal bleeding found a mix of malignant and benign causes: cervical cancer, endometrial cancer, and ovarian cancer accounted for some cases, while endometrial polyps, submucosal fibroids, and uterine prolapse accounted for others.¹⁹ The point is not that postmenopausal bleeding always means cancer. It usually doesn’t. But it always means something, and determining what requires gynecologic evaluation. Women who have already stopped seeing a gynecologist may delay reporting bleeding because they are not sure whom to call.

Pelvic Floor Problems in Later Life

Pelvic organ prolapse and urinary incontinence become increasingly common with age. Among women aged 80 and older who underwent surgery for prolapse, urinary incontinence of some type was present in nearly half.²⁰ Many older women manage prolapse with a pessary, a removable device placed in the vagina for support. About 63% of women attempting a pessary were fitted successfully regardless of age, but long-term use requires regular follow-up: vaginal erosions occurred in about a fifth of long-term users, with women 75 and older more than three times as likely to experience erosions compared with those aged 65 to 74.²¹

These are conditions that require ongoing gynecologic management, often for decades. Pessary use alone demands regular check-ups to inspect for erosion and ensure proper fit. Stopping gynecologic visits eliminates the monitoring that makes pessary use safe and effective.

What Happens When the Gynecologist Has Been Your Primary Source of Preventive Care

For a significant number of women, the gynecologist functions as their main point of contact with the health care system, sometimes the only doctor they see regularly. Data from a survey of women’s preventive service use found that 62% of women were seen by gynecologists alone, 15% by general medical physicians alone, and 23% by both. Women seeing only a gynecologist reported receiving preventive care at rates as high as or higher than those seeing a general medical physician, particularly for gender-specific services like Pap tests, clinical breast exams, and mammograms.²²

When these women are told they no longer need Pap smears, some interpret it as no longer needing the gynecologist at all. And if the gynecologist was their only regular doctor, they may drift out of the health care system entirely. That transition matters. If you have relied on a gynecologist as your primary provider, the point where screening tests wind down is a moment to establish a relationship with a primary care doctor, not a moment to stop going to the doctor.

Barriers Older Women Face in Getting Gynecologic Care

Even when older women do seek gynecologic care, barriers can get in the way. Sensory deficits, physical disability, and cognitive impairment all make it harder both to get to the clinic and to communicate effectively during the visit. Speaking slowly, providing contextual information, and adjusting examination techniques can improve the quality of care, but not all practices are set up to accommodate older patients well.²³ Older women are also less likely to bring up sensitive topics like vaginal symptoms or sexual health on their own, and providers who see mostly younger patients may not think to ask.

There is an ageist assumption, sometimes held by patients and providers alike, that gynecologic health stops mattering at some point. Screening frequency data among Medicare beneficiaries has long shown an inverse relationship between age and screening adherence: in one cohort, 52% of women aged 65 to 69 had annual Pap tests, compared with only 36% of those aged 80 and older. Mammography adherence followed a similar pattern. Among women aged 75 and older, 32% had never had a mammogram at all.²⁴ These gaps suggest that many older women are falling through the cracks, receiving neither the screening they qualify for nor the symptom management they could benefit from.

Sexual Health Does Not Have an Expiration Date

Sexual activity and interest persist well into later life for many women, and so do the medical conditions that can interfere with them. GSM-related pain during sex is treatable. Hypoactive sexual desire disorder is a recognized condition with available therapies. Yet many midlife and older women are unaware that there are medical explanations for the changes they are experiencing, much less that treatments exist. Without that awareness, they do not seek help, and without a provider who asks about sexual function, the topic never comes up. A gynecologist who treats older patients is one of the few providers likely to open that conversation. Stopping visits removes the opportunity.

Hormone Therapy Follow-Up

Women who are on hormone therapy, whether systemic or vaginal, need ongoing monitoring. The decision to start, continue, adjust, or stop hormone therapy is a recurring one that evolves as risks and benefits shift with age. A gynecologist manages this, typically reassessing periodically and weighing the individual’s symptom burden against updated risk information. Women who had early surgical menopause may have been on hormone therapy for decades, and the question of when or whether to taper is genuinely complicated.²⁵ This kind of long-term management does not resolve itself at 65. If anything, the decisions get harder as you age, because the data on very long-term use is sparse and the stakes rise.

Even for women not on systemic hormone therapy, low-dose vaginal estrogen for GSM requires periodic check-ins. Your provider needs to confirm the treatment is working, adjust the dose or formulation if it is not, and make sure no new concerns have appeared. These are straightforward visits, but they do need to happen, and they are a gynecologic visit by definition.